Can a shot tame peanut allergies? small study tests xolair
NCT ID NCT00382148
First seen Jun 09, 2026
Summary
This phase 2 study tested the drug Xolair (omalizumab) in 11 people with peanut allergies who had already completed a previous trial. The goal was to see if the drug could reduce serious allergic reactions. Participants received regular injections of Xolair and reported any peanut exposures. The study was small and open-label, meaning everyone knew they were getting the drug, so results are preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEANUT ALLERGY are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
omalizumab (Xolair)
What this could lead to
If it works, this could point toward a treatment that helps people with peanut allergies tolerate accidental exposure.
What could go wrong
This is a very small, early-phase study with only 11 people, so results may not apply to everyone. The drug also requires ongoing injections and is not a cure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.